Lilly 4th-qtr profits and sales beat expectations

30 January 2021

Shares of US pharma major Eli Lilly (NYSE: LLY) were up 2.1% at $214.6 in pre-market trading, as the company reported financial results for the fourth-quarter and full year 2020.

Net earnings rose 41% to $2.12 billion, or $2.32 per share, in the fourth quarter from $1.50 billion, or $1.64 per share, a year earlier. Excluding items, the company earned $2.75 per share, beating analysts’ estimates of $2.35 per share.

Group sales rose 21.7% to $7.44 billion, above the FactSet consensus of $7.27 billion, as the company booked $850 million in US revenue for bamlanivimab, its treatment for mile to moderate COVID-19 that has been granted Emergency Use Authorization.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK